載入中
NASDAQHealthcareBiotechnology
最新資料
US$8.565
−US$4.815 · -35.99%
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
收盤時
US$8.565
−US$4.815 · -35.99%
盤中時間採用ET。市場資料可能有所延遲。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日內區間
目前US$8.565
52週區間
目前US$8.565
盤中時間採用ET。市場資料可能有所延遲。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日內區間
目前US$8.565
52週區間
目前US$8.565
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 5000萬 USD | — | — |
| 銷貨成本 | — | 25.8萬 USD | — | — | — |
| 毛利 | — | −25.8萬 USD | 5000萬 USD | — | — |
| 研究與開發 | 5152.2萬 USD | 3816.4萬 USD | 2760.3萬 USD | 1689.4萬 USD | 2236萬 USD |
| 銷售、一般及管理費用 | 1653.7萬 USD | 1247.2萬 USD | 632萬 USD | 582.6萬 USD | 628.7萬 USD |
| 營業費用 | 6805.9萬 USD | 5063.6萬 USD | 6607.7萬 USD | 2272萬 USD | 2864.7萬 USD |
| 利息收入 | 824.6萬 USD | 890.5萬 USD | 460.6萬 USD | 76.1萬 USD | 7.7萬 USD |
| 利息支出 | — | — | 20.8萬 USD | 38.8萬 USD | 33.2萬 USD |
| 折舊和攤銷 | 32.3萬 USD | 25.8萬 USD | 19.5萬 USD | 32.9萬 USD | 32.5萬 USD |
| 營業利益 | −6805.9萬 USD | −5089.4萬 USD | −1607.7萬 USD | −2272萬 USD | −2864.7萬 USD |
| 淨利 | −5997.8萬 USD | −4225.8萬 USD | 2272萬 USD | −2425.3萬 USD | −2900.1萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1595.19萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM967.84萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF498萬0.01%954億 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB310.45萬0.03%108.2億 USD0.44%US$204.26-1.08%
State Street SPDR S&P Pharmaceuticals ETFXPH299.94萬0.65%4.69億 USD0.35%US$64.01-0.99%
Vanguard Russell 2000 ETFVTWO251.11萬0.01%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA213.86萬0.01%218.24億 USD0.03%US$32.66-0.40%
Dimensional - US Small Cap ETFDFAS123.51萬0.00%338.69億 USD0.31%US$78.17-0.23%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
